Authors' recommendations: Uveitis affects the lining of the eye. It is an inflammation that can lead to eye pain, eye redness, headaches, and visual problems that can become permanent. In many cases the cause of uveitis is unknown, but it is much more common in patients who are affected by a form of childhood arthritis called juvenile idiopathic arthritis (JIA). Adalimumab is a drug that is already used to treat JIA. It is injected under the skin once every two weeks. Some studies have suggested that it could be effective in treating the uveitis associated with JIA in patients who haven't responded to the standard treatments for this condition. If adalimumab is licensed for use in the UK, it could be a new treatment option for children and adolescents with uveitis associated with JIA who are not responding to standard drug treatments.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/adalimumab-humira-for-uveitis-in-paediatric-patients-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)